Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialThomas L Holland, Robert C. Hyzy, Andrew M. Vekstein et al.|The Lancet Respiratory Medicine|2022Cited by 127
Quantitative Alterations of the Functionally Distinct Subsets of CD4 and CD8 T Lymphocytes in Asymptomatic HIV InfectionJosé M. Benito, Eduardo Fernández‐Cruz, J M Zabay et al.|Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology|1997Cited by 86
Increased levels of activated subsets of CD4 T cells add to the prognostic value of low CD4 T cell counts in a cohort of HIV-infected drug usersJavier Carbone, Eduardo Fernández‐Cruz, Juana Gil et al.|AIDS|2000Cited by 75